Preclinical screening should evaluate the combinatorial efficacy of OC with ERK1/2 inhibitors (e.g., ulixertinib) in Consensus Molecular Subtype 4 (CMS4) CRC models characterized by high TNF-α expression. Here, TNF is linked to colorectal carcinoma.